Serial No: 09/760,807 Docket No: 12013-58101

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Maris Palasis Application No: 09/760,807

Patent No. : 7,179,251 B2 Customer No: 23838

Filed: : January 17, 2001 Confirmation No: 4398

Issued : February 20, 2007 Art Unit: 3763

Title: : THERAPEUTIC DELIVERY BALLOON

Examiner : Loan H. Thanh

REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 C.F.R. § 1.323

ATTN: Certificate of Correction Branch

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Patentee hereby requests that the enclosed Certificate of Correction be issued for the above Patent under authority of 35 U.S.C. § 255.

The errors that appear in this patent are of a clerical, typographical or minor nature or character and occurred in good faith. Correction thereof does not involve changes in the patent as would constitute new matter or would require reexamination. In particular:

Col. 1, line 22, change "shaped" to -- shape, --.

Col. 3, line 49, change "heart," to -- heart; --. Line 57, change "livers," to -- liver, --.

Col. 4, line 34, change "inflated" to -- inflated, --. Line 59, change "fluid" to -- fluid, --.

Col. 5, line 65, change "601" to -- 601, --.

Serial No: 09/760,807 Docket No: 12013-58101

Col. 6, lines 2 and 3, change "distillation bladder" to -- dilation bladder --.

```
Col. 7, line 9, change "wall," to -- wall; --.
Line 37, change "end," to -- end; --.
```

Col. 8, line 37, change "virus" to -- viruses --.
Line 41, change "includes" to -- include --.
Lines 56 and 57, change "viral, liposomes" to -- viral liposomes --.

Col. 9, line 13, change "nitorfurantoin" to -- nitrofurantoin --.
Line 15, change "lisidomine" to -- linsidomine --.
Line 21, change "Warafin" to -- Warfarin --.
Line 24, change "promotors" to -- promoters --.
Line 26, change "promotors;" to -- promoters; --.
Line 34, change "endogeneus vascoactive" to -- endogenous vasoactive --.

Col. 10, line 8, change ("BMP's"). to -- ("BMPs").

Line 12, change "BMP's" to -- BMPs --.

Line 19, change "DNA's" to -- DNAs --.

The Commissioner is hereby authorized to charge payment of the 37 C.F.R. §1.20(a) Certificate of Correction fee of \$100.00 to the deposit account of Kenyon & Kenyon, deposit account number 11-0600. The Commissioner is also authorized to charge any additional fees or credit any overpayment in connection with this paper to Deposit Account No. 11-0600.

> Respectfully submitted, KENYON & KENYON LLP

Dated: August 21, 2008 /Jocelyn D. Ram/

Jocelyn Ram Registration No. 54,898

KENYON AND KENYON LLP 1500 K Street, N.W., Suite 700 Washington, D.C. 20005 Tel: (202) 220-4200 Fax: (202) 220-4201 733959

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO: 7,179,251 B2 Page 1 of 2

APPLICATION NO.: 09/760.807

ISSUE DATE : February 20, 2007
INVENTOR(S) : Maria Palasis

It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

Col. 1, line 22, change "shaped" to -- shape, --.

Col. 3, line 49, change "heart," to -- heart; --. Line 57, change "livers," to -- liver, --.

Col. 4, line 34, change "inflated" to -- inflated, --.
Line 59, change "fluid" to -- fluid, --.

Col. 5, line 65, change "601" to -- 601, --.

Col. 6, lines 2 and 3, change "distillation bladder" to -- dilation bladder --.

Col. 7, line 9, change "wall," to -- wall; --. Line 37, change "end," to -- end; --.

Col. 8, line 37, change "virus" to -- viruses --.
Line 41, change "includes" to -- include --.
Lines 56 and 57, change "viral, liposomes" to -- viral liposomes --.

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Kenyon & Kenyon LLP 1500 K Street, NW, Suite 700 Washington, D.C. 20005-1257

This collection of information is required by 3T CFR 1,322, 1,323, and 1,324. The information is required by collection cerebral period within the file (and by the USPTO) to process in application. Confiderability is governed by 3D LIS.4. C12 and 3T CFR 1,14. This collection is estimated to take 1,0 hour to complete, including gathering, preparing, and submitting the completed application from the tuSPTO. Time will vary depending upon the individual care. Any commetted not be amount of time by the increase to the Charlest increase to the Charlest increase and the control of the collection of the control of the collection of the control of the collection of the collectio

(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO: 7.179.251 B2 Page 2 of 2

APPLICATION NO.: 09/760.807

ISSUE DATE : February 20, 2007

INVENTOR(S) : Maria Palasis

It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

Col. 9, line 13, change "nitorfurantoin" to -- nitrofurantoin --.
Line 15, change "lisidomine" to -- linsidomine --.

Line 21, change "Warafin" to -- Warfarin --.

Line 24, change "promotors" to -- promoters --.

Line 26, change "promotors;" to -- promoters; --.

Line 34, change "endogeneus vascoactive" to -- endogenous vasoactive --.

Col. 10, line 8, change ("BMP's"). to -- ("BMPs"). line 12, change "BMP's" to -- BMPs --. Line 19, change "DNA's" to -- DNAs --.

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Kenyon & Kenyon LLP 1500 K Street, NW, Suite 700 Washington, D.C. 20005-1257

This collection of information is required by 3T CFR 1,322, 1,323, and 1,324. The information is required to obtain or retain a benefit by the public which is to the [indirect by the DFP to process) an application. Confiderability is governed by 50 List. 0.12 and 37 CFR 1.14. This collection is estimated to take \$1.0 hour to complete, including gathering, pregaring, and submitting the completed application form to the LSPTO. Time will vary depending upon the individual case. Any comments on the encount of time by unrequire to complete in both made to suggestion for reducing the business about the centre of the DFP the individual case. Any comments on the encount of time by unrequire to complete the both made to suggestion for the during the business about the centre of the DFP the individual case. Any comments on the about all of the centre of the DFP the Individual case. Any comments on the about all of the about the properties of the centre of the DFP the Individual case. Any comments of the about the DFP the Individual case. Any comments of the Individual case. Any